Skip to main content

Table 1 Patient and tumor characteristics relative to chemotherapy

From: Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer

  Anthracycline/taxane-based Platinum/taxane-based
n (%) or mean (SD) n (%) or mean (SD)
Overall 55 66
Age at first diagnosis 48.3 (9.6) 50.3 (12.1)
Age
 < 45 y 19 (34.5) 21 (31.8)
 45–54 y 21 (38.2) 19 (28.8)
 > 54 y 15 (27.3) 26 (39.4)
Tumor size
 ≤ 2 cm 20 (36.4) 27 (40.9)
 > 2 cm 35 (63.6) 39 (59.1)
Grading
 1 or 2 10 (18.2) 10 (15.2)
 3 45 (81.8) 56 (84.8)
Ki-67
 < 36% 13 (23.6) 14 (21.2)
 ≥ 36% 42 (76.4) 52 (78.8)
pCR
 No 32 (58.2) 33 (50.0)
 Yes 23 (41.8) 33 (50.0)
  1. pCR pathologic complete response, SD standard deviation